dabigatran

Dabigatran is an oral anticoagulant belonging to a class of medicines called direct oral anticoagulants (DOACs). It is administered as dabigatran etexilate, which is converted in the body to its active form, dabigatran. The medication works by directly inhibiting thrombin (factor IIa), an enzyme required for converting fibrinogen into fibrin during blood clot formation. Dabigatran is commonly used to reduce the risk of stroke and systemic embolism in people with non-valvular atrial fibrillation and for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Because it reduces blood clotting, the main potential side effect is bleeding. Kidney function and other individual factors may influence its use and dosing.

Dabigatran is a blood thinner medicine that helps prevent harmful blood clots. It works by blocking a clotting protein called thrombin, reducing the chance of problems such as stroke or certain types of blood clots.

• Anticoagulant (“blood thinner”) medication • Belongs to direct oral anticoagulants (DOACs) • Works by directly blocking thrombin (factor IIa) • Helps prevent formation of harmful blood clots • Used in conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) • Does not dissolve existing clots but helps prevent clot growth and new clots • Main possible side effect is increased risk of bleeding • Kidney function may affect dosing and suitability • Should be taken only as prescribed by a healthcare professional